Stockreport

Instil Bio's Subsidiary Discontinues Clinical Development of AXN-2510 and Terminates License and Collaboration Agreement with ImmuneOnco [Yahoo! Finance]

Instil Bio, Inc.  (TIL) 
NASDAQ:AMEX Investor Relations: nasdaq.com/symbol/til
PDF subsidiary of Instil, has decided to discontinue clinical development of AXN-2510 and that Axion and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX: 1541.HK) (“Immu [Read more]